AliHealth Announces the Completion of Joint Investment in Yingsheng Biology

(VCBeat) Apr. 08, 2021 -- Recently, AliHealth has completed the joint investment in Shandong Yingsheng Biotechnology Co., Ltd. ("Yingsheng Biology"), a biotech company in clinical mass spectrometry (MS) market. Zijin Hongyun Fund, a Co-GP capital jointly managed by Huatai Zijin and AliHealth led the latest round, which will support Yingsheng Biology for its research and development, marketing and capacity expansion.

MS, as a cutting-edge innovation in the field of medical technology, the advantages of high sensitivity, high specificity, high accuracy, wide linear range, and high throughput. It has great application potential in multiple fields, such as clinical biochemistry inspection, immunology, microbiological, and molecular biological diagnosis. It's called the next technological tipping point in vitro diagnostics (IVD).

"MS is the next useful tool in precision medicine. AliHealth has participated in the scientific research, diagnosis and treatment of major diseases through its Internet business. Meanwhile, in exploring and planning for the future, AliHealth is committed to providing users with accurate and convenient medical and healthcare services and helping more people improve the quality of life." said the related person in charge of AliHealth.

Established in 2009, Yingsheng Biology is a pioneer in technology development, quality control and technical services in the field of clinical MS in China. It mainly provides customers with a full set of solutions covering sample pre-treatment, mass spectrometry detection, diagnostic reagents and maintenance services. The company has built a leading gene testing platform and an MS detection platform for birth defect screening, disease prevention and human health management.

The completion of this joint investment is considered to be AliHealth's continuous advance in the frontier of precision medicine, as well as another achievement of its active business layout of cutting-edge technologies in the medical field in recent years. In March this year, AliHealth completed the strategic investment in LinkDoc, a unicorn of digital solutions in the field of oncology. The two companies will build a full-disease cycle service platform for Chinese cancer patients to provide users with accurate and convenient services and improve the disease treatment and service.